As part of this collaboration, GALT will support four research projects that will use the company's Prospector high-throughput microbial isolation and cultivation system to generate banks of live microbial isolates.
The isolates will be used in studies to develop a more detailed understanding in critical areas of microbiome research: how the microbiome causes different individuals to digest food differently, the microbial basis of disease in a major food crop, how to improve our ability to cultivate microbes from soil, and how the soil microbiome interacts with crop plants and influences crop productivity.
The GALT Prospector system is an array-based platform for microbiome research and product development that enables scientists to cultivate target microbes from complex samples using a massively scalable, easy-to-use workflow.
The system improves the capability and capacity of microbiome research laboratories to screen, isolate and analyze difficult-to-culture or less abundant microbes from complex microbiome samples.
The Penn State Microbiome Center supports transformative, interdisciplinary research in microbiomes by fostering long-term working relationships while simultaneously providing infrastructure and resources needed for increasing the diversity and breadth of microbiome research and educational opportunities at Penn State.
Units involved in the center include the colleges of Agricultural Sciences, Communications, Earth and Mineral Sciences, Engineering, Health and Human Development, Information Sciences and Technology, and Medicine, and the Eberly College of Science.
Also participating are the Huck Institutes of the Life Sciences, the Social Science Research Institute, the Institutes of Energy and the Environment, and the Institute for Computational and Data Sciences.
Active members also come from the Arts Design Research Incubator and from other Penn State campuses.
GALT, a privately held company based in Silicon Valley, is a developer of cultivation and screening platforms for microbiome research and microbial product development, addressing high-impact markets including human health, agriculture, environmental science, and microbial products for industrial use.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA